These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 11866276

  • 21. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.
    Becker K, Niederau C, Frieling T.
    Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008
    [Abstract] [Full Text] [Related]

  • 22. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.
    Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN.
    Am J Gastroenterol; 2009 Jul; 104(7):1754-63. PubMed ID: 19455122
    [Abstract] [Full Text] [Related]

  • 23. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database.
    Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Nørregaard P, Moesgaard F, Bendtsen F, Munkholm P, DCCD study group.
    Am J Gastroenterol; 2006 Jun; 101(6):1274-82. PubMed ID: 16771949
    [Abstract] [Full Text] [Related]

  • 24. Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role.
    Parente F, Cucino C, Bollani S, Imbesi V, Maconi G, Bonetto S, Vago L, Bianchi Porro G.
    Am J Gastroenterol; 2000 Mar; 95(3):705-11. PubMed ID: 10710061
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
    Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A.
    Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
    [Abstract] [Full Text] [Related]

  • 27. [Epidemiology in inflammatory bowel disease in five areas of Asturias. Spain].
    Saro Gismera C, Riestra Menéndez S, Sánchez Fernández R, Milla Crespo A, Lacort Fernández M, Argüelles Fernández G, Chobak Z, Florido Mancheño JI, Antón Magarzo JL, Altadill Arregui A, Vizoso F, Pineda García E, Fernández de Ocariz Archs E, Albert Colomer J, García Pérez J, López Rivas L, Lombraña JL.
    An Med Interna; 2003 May; 20(5):232-8. PubMed ID: 12831296
    [Abstract] [Full Text] [Related]

  • 28. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase.
    Rocha R, Santana GO, Almeida N, Lyra AC.
    Br J Nutr; 2009 Mar; 101(5):676-9. PubMed ID: 18631418
    [Abstract] [Full Text] [Related]

  • 29. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire.
    Casellas F, Alcalá MJ, Prieto L, Miró JR, Malagelada JR.
    Am J Gastroenterol; 2004 Mar; 99(3):457-61. PubMed ID: 15056085
    [Abstract] [Full Text] [Related]

  • 30. [Extra-intestinal manifestation of IBD in Veszprém county (of Hungary): results of a 25-years follow-up study].
    Lakatos L, Pandur T, Dávid G, Balogh Z, Küronya P, Tollas A, Lakatos PL.
    Orv Hetil; 2003 Oct 05; 144(40):1965-75. PubMed ID: 14626638
    [Abstract] [Full Text] [Related]

  • 31. [Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease].
    Stawarski A, Iwańczak B, Krzesiek E, Iwańczak F.
    Pol Merkur Lekarski; 2006 Jan 05; 20(115):22-5. PubMed ID: 16617729
    [Abstract] [Full Text] [Related]

  • 32. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
    Valentini L, Wirth EK, Schweizer U, Hengstermann S, Schaper L, Koernicke T, Dietz E, Norman K, Buning C, Winklhofer-Roob BM, Lochs H, Ockenga J.
    Nutrition; 2009 Feb 05; 25(2):172-81. PubMed ID: 18849144
    [Abstract] [Full Text] [Related]

  • 33. [Serum bone marker measurements in bone metabolism disorders associated with inflammatory bowel diseases].
    Miheller P, Tóth M, Molnár E, Zágoni T, Rácz K, Tulassay Z.
    Orv Hetil; 2001 Jul 22; 142(29):1557-60. PubMed ID: 11494747
    [Abstract] [Full Text] [Related]

  • 34. [Inflammatory bowel diseases in children].
    Langholz E, Munkholm P, Krasilnikoff PA, Binder V.
    Ugeskr Laeger; 1998 Sep 21; 160(39):5648-54. PubMed ID: 9771057
    [Abstract] [Full Text] [Related]

  • 35. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
    Dimopoulou I, Galani H, Dafni U, Samakovii A, Roussos C, Dimopoulos MA.
    Cancer; 2002 Jan 15; 94(2):452-8. PubMed ID: 11900231
    [Abstract] [Full Text] [Related]

  • 36. Malnutrition in inflammatory bowel disease patients in northern India: frequency and factors influencing its development.
    Ghoshal UC, Shukla A.
    Trop Gastroenterol; 2008 Jan 15; 29(2):95-7. PubMed ID: 18972769
    [Abstract] [Full Text] [Related]

  • 37. Increased prevalence of lactose malabsorption in Crohn's disease patients at low risk for lactose malabsorption based on ethnic origin.
    Mishkin B, Yalovsky M, Mishkin S.
    Am J Gastroenterol; 1997 Jul 15; 92(7):1148-53. PubMed ID: 9219788
    [Abstract] [Full Text] [Related]

  • 38. Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease.
    Palatka K, Serfozo Z, Veréb Z, Hargitay Z, Lontay B, Erdodi F, Bánfalvi G, Nemes Z, Udvardy M, Altorjay I.
    Scand J Gastroenterol; 2005 Jun 15; 40(6):670-80. PubMed ID: 16036527
    [Abstract] [Full Text] [Related]

  • 39. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study.
    Chow DK, Sung JJ, Tsoi KK, Wong VW, Wu JC, Leong RW, Chan FK.
    Aliment Pharmacol Ther; 2009 Apr 15; 29(8):843-54. PubMed ID: 19154567
    [Abstract] [Full Text] [Related]

  • 40. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.
    Am J Gastroenterol; 2008 Jan 15; 103(1):162-9. PubMed ID: 17916108
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.